Eligible self-pay patients can fill oral semaglutide through GoodRx-participating pharmacies nationwide with transparent cash ...

Cell and gene therapies (CGTs) are reshaping the specialty pharmacy and distribution ecosystem, introducing a level of ...

In this week’s Pharma Pulse, the launch of the Ember Cube 2, exclusive policy insights from Asembia AXS26, a record-breaking ...

CoverMyMeds' Miranda Delatore and Megan Wetzel discuss AI in prior auth and fixing specialty access bottlenecks upstream. In ...

Will Shrank, MD, evaluates opportunities and challenges in specialty pharma over the next few years. In his interview with ...

Gross-to-net concessions exceeding half of U.S. brand revenue make minor contracting and payment inefficiencies translate into hundreds of millions in leakage or compliance risk. Legacy revenue ...

Scaling from ultra-rare volumes to mainstream indications threatens redundancy-heavy manufacturing and logistics, forcing ...

PBM reform is accelerating via FTC settlements and CAA 2026, mandating data reporting, rebate pass-through in Part D, ...

Structural disruption pressures are rising, making safety stock and excess capacity insufficient as primary risk buffers across highly regulated, temperature-sensitive networks. Digital-twin ...

DSCSA-era serialization and traceability performance depends on sanitized, aggregated data lakes enabling interoperable tooling and high-integrity datasets for AI model training and decision-making.

Eli Lilly has entered a definitive agreement to acquire Kelonia Therapeutics for up to $7 billion. The centerpiece of the ...

Live from Asembia AXS26, Jessica Lovett explains what real world evidence and data matters most in making decisions around specialty medicines.